Value Collaborative Videos


On June 29, 2017, the Turning the Tide Against Cancer National Conference convened leaders from across the oncology community to explore the role of the patient across the continuum of cancer research and care and identify strategies that policymakers might consider implementing to support meaningful patient engagement and deliver value to patients.

At the conference, The Value Collaborative sponsored a panel on Partnering to Deliver High-Value Care for Patients, to examine how health care stakeholders are partnering on innovative approaches to support the delivery of high-value care. The discussion brought together executives from industry and non-profit sectors, and focused on why partnerships deliver better value for patients, which collaborative strategies improve value, and how other executives can operationalize similar strategies to support high quality patient care.


  • Stephen J. Ubl, president and CEO, Pharmaceutical Research and Manufacturers of America (PhRMA)
  • David Lansky, Ph.D., president and CEO, Pacific Business Group on Health
  • J. Leonard Lichtenfeld, M.D., deputy CMO, American Cancer Society
  • Bill Martin, vice president/general manager, Accredo Commercial and Trade Relations, Express Scripts
  • Lori M. Reilly, Esq., executive vice president, Policy, Research & Membership, PhRMA


Susan Dentzer, president and CEO, Network for Excellence in Health Innovation

The rapidly changing health care landscape in the United States is witnessing a transition from a volume-based to a value-based reimbursement structure. In the process, patient care is also changing.

What steps are biopharmaceutical companies, insurers, and providers taking to create a more value-driven health care system? Is there a role that policymakers can or should play to ensure that this approach improves outcomes and what are the implications for patients?

On June, 13, 2017, The Hill convened policymakers, health industry representatives, and patient advocates for a conversation about the impact of outcomes-based care. 


  • Senator Bill Cassidy (R-LA), member, Senate Committee on Health, Education, Labor & Pensions 
  • Congresswoman Doris Matsui (D-CA), member, House Energy and Commerce Committee
  • Liz Fowler, vice president, Global Health Policy, Johnson & Johnson
  • Patrick Geraghty, CEO, GuideWell and Florida Blue
  • Marilyn Serafini, health care policy consultant
  • Pamela Sutton-Wallace, CEO, University of Virginia Medical Center
  • Stephen J. Ubl, president and CEO, PhRMA
  • Cynthia Zagieboylo, president and CEO, National Multiple Sclerosis Society


  • Bob Cusack, editor-in-chief, The Hill
  • Kim Dixon, policy editor, The Hill

Across the health care system there is a movement to better pay for services based on outcomes, and industry leaders are increasingly coalescing around private market solutions that produce and reward better value for patients.

On February 23, 2017, The Value Collaborative partnered with Morning Consult to convene representatives from the payer, provider and patient communities to discuss new innovative ways to pay for medicines and the policy solutions needed to advance value-driven health care.


  • Tanisha Carino Ph.D., vice president, U.S. Public Policy, GlaxoSmithKline
  • Samuel Nussbaum, MD, senior fellow, USC Schaeffer Center & former CMO, Anthem Inc.
  • Marc Boutin, JD, CEO, National Health Council
  • Patricia J. Goldsmith, CEO, CancerCare
  • Clifford A. Hudis, MD, CEO, American Society of Clinical Oncology
  • Stephen J. Ubl, president and CEO, Pharmaceutical Research and Manufacturers of America (PhRMA)


Michael Ramlet, co-founder & CEO, Morning Consult